Welcome to our dedicated page for ACRX news (Ticker: ACRX), a resource for investors and traders seeking the latest updates and insights on ACRX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ACRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ACRX's position in the market.
AcelRx Pharmaceuticals (Nasdaq: ACRX) announced an investigator-initiated study with Cleveland Clinic to evaluate the impact of DSUVIA on post-operative recovery in orthopedic surgery patients. Preliminary data suggests DSUVIA reduces opioid use and discharge time from the PACU. DSUVIA, approved by the FDA in November 2018, is a sublingual sufentanil tablet providing rapid analgesia in medically supervised settings. AcelRx aims to further demonstrate DSUVIA's efficacy and safety through ongoing and future studies.
AcelRx Pharmaceuticals (NASDAQ: ACRX) announced a study published in the Journal of Clinical Anesthesia and Pain Management, highlighting the effectiveness of DSUVIA in reducing opioid usage during outpatient surgeries. The study reported that patients receiving DSUVIA had a 34% faster discharge from the postanesthesia care unit (PACU) and required significantly fewer opioids compared to those receiving standard IV opioids. With 127 patients evaluated, DSUVIA reduced overall opioid consumption by over 50%. Experts believe this could lead to a paradigm shift in pain management protocols.
AcelRx Pharmaceuticals (Nasdaq: ACRX) reported its Q2 2020 results, achieving progress amidst COVID-19 challenges. Key highlights include:
- Q2 net revenues of $2.9 million, primarily from Zalviso® agreement.
- Net loss of $6.6 million, down from $12.4 million in Q2 2019.
- Cash balance of $43.7 million as of June 30, 2020.
- Milestone C approval for DSUVIA from the Department of Defense, with expected orders of ~$30 million over three years.
- Distribution agreement with Zimmer Biomet to expand DSUVIA reach in dental markets.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will release its second quarter financial results on August 10, 2020, after market close. A conference call and webcast hosted by management will occur at 4:30 p.m. ET on the same day to review the results and provide updates. The webcast can be accessed via the company's website. AcelRx specializes in innovative therapies, with its approved product, DSUVIA, indicated for acute pain management in medically supervised settings, and its candidate, Zalviso, under development.
AcelRx Pharmaceuticals (Nasdaq: ACRX) has announced a partnership with Zimmer Biomet to exclusively market DSUVIA®, a sublingual opioid for managing acute pain during dental and oral surgeries in the U.S. DSUVIA is designed to mitigate the challenges of IV administration, offering a non-invasive alternative. This strategic alliance aims to support dental professionals amid millions of oral surgeries annually. DSUVIA is indicated for use in certified healthcare settings for adults and will be available post-licensing.